David Liberg

1.6k total citations
38 papers, 1.2k citations indexed

About

David Liberg is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, David Liberg has authored 38 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Immunology, 12 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in David Liberg's work include Immune Cell Function and Interaction (10 papers), Cancer Immunotherapy and Biomarkers (7 papers) and T-cell and B-cell Immunology (7 papers). David Liberg is often cited by papers focused on Immune Cell Function and Interaction (10 papers), Cancer Immunotherapy and Biomarkers (7 papers) and T-cell and B-cell Immunology (7 papers). David Liberg collaborates with scholars based in Sweden, United States and Germany. David Liberg's co-authors include Tomas Leanderson, Mikael Sigvardsson, Fredrik Ivars, Anders Olsson, Per Björk, Thomas Vogl, Johannes Roth, Martin Stenström, Anders Björk and Krister Bamberg and has published in prestigious journals such as Journal of Biological Chemistry, Immunity and The Journal of Immunology.

In The Last Decade

David Liberg

35 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Liberg Sweden	16	655	583	179	151	135	38	1.2k
Minghua Zhu United States	24	675 1.0×	1.1k 1.9×	279 1.6×	149 1.0×	111 0.8×	66	1.9k
Sagar Chhangawala United States	14	876 1.3×	710 1.2×	338 1.9×	381 2.5×	233 1.7×	21	1.8k
Floris P. J. van Alphen Netherlands	18	481 0.7×	423 0.7×	206 1.2×	118 0.8×	86 0.6×	47	1.3k
H. Elizabeth Broome United States	12	516 0.8×	385 0.7×	192 1.1×	110 0.7×	46 0.3×	29	1.1k
Pia Rantakari Finland	22	565 0.9×	540 0.9×	283 1.6×	175 1.2×	88 0.7×	46	1.5k
Jagan Muppidi United States	16	760 1.2×	647 1.1×	221 1.2×	171 1.1×	30 0.2×	33	1.3k
Luis Caveda Italy	13	1.1k 1.6×	324 0.6×	149 0.8×	155 1.0×	87 0.6×	16	1.7k
Ladina Di Rago Australia	19	601 0.9×	523 0.9×	304 1.7×	143 0.9×	73 0.5×	38	1.4k
Nikunj Sharma United States	12	963 1.5×	543 0.9×	81 0.5×	178 1.2×	78 0.6×	20	1.6k
Jessica Pruessmeyer Germany	14	611 0.9×	252 0.4×	356 2.0×	237 1.6×	119 0.9×	15	1.3k

Countries citing papers authored by David Liberg

Since Specialization

Citations

This map shows the geographic impact of David Liberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Liberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Liberg more than expected).

Fields of papers citing papers by David Liberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Liberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Liberg. The network helps show where David Liberg may publish in the future.

Co-authorship network of co-authors of David Liberg

This figure shows the co-authorship network connecting the top 25 collaborators of David Liberg. A scholar is included among the top collaborators of David Liberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Liberg. David Liberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marcone, Rachel, Elin Jaensson Gyllenbäck, David Liberg, et al.. (2025). HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine. Cancer Discovery. 15(7). 1458–1483.

Lindkvist, Madelene, Geena Varghese Paramel, Camilla Rydberg Millrud, et al.. (2025). IL1RAP Expression in Human Atherosclerosis: A Target of Novel Antibodies to Reduce Vascular Inflammation and Adhesion. Journal of the American Heart Association. 14(10). e039557–e039557. 1 indexed citations

Rattik, Sara, Xiang Zhou, Yinan Li, et al.. (2024). Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis. Annals of the Rheumatic Diseases. 83(9). 1156–1168. 16 indexed citations

Talor, Monica V., Sara Rattik, Elin Jaensson Gyllenbäck, et al.. (2024). IL1RAP Blockade With a Monoclonal Antibody Reduces Cardiac Inflammation and Preserves Heart Function in Viral and Autoimmune Myocarditis. Circulation Heart Failure. 17(12). e011729–e011729. 3 indexed citations

Fields, James K., Elin Jaensson Gyllenbäck, Sara Rattik, et al.. (2024). Antibodies targeting the shared cytokine receptor IL-1 receptor accessory protein invoke distinct mechanisms to block all cytokine signaling. Cell Reports. 43(5). 114099–114099. 7 indexed citations

Cutsem, Eric Van, Jashodeep Datta, Manuel Hidalgo, et al.. (2024). Abstract C002: Interleukin-1 receptor accessory protein (IL1RAP) overexpression is associated with worse prognosis in PDAC and is targetable by nadunolimab. Cancer Research. 84(2_Supplement). C002–C002.

Depuydt, Marie A.C., Irena Ljungcrantz, Fong To, et al.. (2024). Interleukin-1 receptor accessory protein blockade limits the development of atherosclerosis and reduces plaque inflammation. Cardiovascular Research. 120(6). 581–595. 7 indexed citations

Fields, James K., Erik H. Klontz, G. Forsberg, et al.. (2021). Molecular Basis of Selective Cytokine Signaling Inhibition by Antibodies Targeting a Shared Receptor. Frontiers in Immunology. 12. 779100–779100. 19 indexed citations

Chakraborty, Paramita, Per Björk, Eva Källberg, et al.. (2015). Vesicular Location and Transport of S100A8 and S100A9 Proteins in Monocytoid Cells. PLoS ONE. 10(12). e0145217–e0145217. 10 indexed citations

10.

Olsson, Anders, Anette Sundstedt, Pascale Plas, et al.. (2015). Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment. Journal for ImmunoTherapy of Cancer. 3(1). 53–53. 56 indexed citations

11.

Leanderson, Tomas, David Liberg, & Fredrik Ivars. (2015). S100A9 as a Pharmacological Target Molecule in Inflammation and Cancer. Endocrine Metabolic & Immune Disorders - Drug Targets. 15(2). 97–104. 18 indexed citations

12.

Källberg, Eva, Thomas Vogl, David Liberg, et al.. (2012). S100A9 Interaction with TLR4 Promotes Tumor Growth. PLoS ONE. 7(3). e34207–e34207. 115 indexed citations

13.

Källberg, Eva, Martin Stenström, David Liberg, Fredrik Ivars, & Tomas Leanderson. (2012). CD11b+Ly6C++Ly6G- cells show distinct function in mice with chronic inflammation or tumor burden. BMC Immunology. 13(1). 69–69. 26 indexed citations

14.

Thompson, Elizabeth C., Bradley S. Cobb, Pierangela Sabbattini, et al.. (2007). Ikaros DNA-Binding Proteins as Integral Components of B Cell Developmental-Stage-Specific Regulatory Circuits. Immunity. 26(3). 335–344. 142 indexed citations

15.

Thompson, Elizabeth, Bradley S. Cobb, Pierangela Sabbattini, et al.. (2007). Ikaros DNA-Binding Proteins as Integral Components of B Cell Developmental-Stage-Specific Regulatory Circuits. Immunity. 26(4). 533–533. 2 indexed citations

16.

Carlsson, R., Kaisa Thorell, David Liberg, & Tomas Leanderson. (2006). SPI-C and STAT6 can cooperate to stimulate IgE germline transcription. Biochemical and Biophysical Research Communications. 344(4). 1155–1160. 10 indexed citations

17.

Liberg, David, Stephen T. Smale, & Matthias Merkenschlager. (2003). Upstream of Ikaros. Trends in Immunology. 24(11). 567–570. 18 indexed citations

18.

Liberg, David, et al.. (2002). The EBF/Olf/Collier Family of Transcription Factors: Regulators of Differentiation in Cells Originating from All Three Embryonal Germ Layers. Molecular and Cellular Biology. 22(24). 8389–8397. 85 indexed citations

19.

Carlsson, R., et al.. (2002). Genomic structure of mouse SPI-C and genomic structure and expression pattern of human SPI-C. Gene. 299(1-2). 271–278. 12 indexed citations

20.

Liberg, David, Mikael Sigvardsson, & Tomas Leanderson. (1997). OCT proteins are qualitative rather than quantitative regulators of κ transcription. Molecular Immunology. 34(14). 979–986. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact